Trial Profile
Safety of quitting imatinib in Japanese chronic myelogenous leukemia patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Myeloid leukaemia
- Focus Therapeutic Use
- Acronyms JASQIM
- 17 May 2016 New trial record